Currently Viewing:
Patient-Centered Oncology Care
Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says
November 17, 2017
Navigators Offer Touch Points on Patients' Cancer Journey
November 18, 2017
Documenting When a Patient Falls Outside a Recommended Pathway
November 20, 2017
Ian Manners: Addressing Financial Toxicity for Patients
November 29, 2017
The Importance of Teamwork in Oncology Care Transitions
November 30, 2017
Dr Brenton Fargnoli Highlights How Practices Can Prepare for Downside Risk
December 15, 2017
Kathleen Lokay: Clinical Pathways Can Prevent Prior Authorization Delays
December 24, 2017
Torrie Fields: Data Collection Takes the Guesswork Out of Care
January 01, 2018
Kathleen Lokay on How Data Generation Informs Clinical Pathways
January 16, 2018
Dr Brenton Fargnoli Discusses the Creation of a Learning Health System
January 25, 2018
Kathleen Lokay on Educating Patients on Treatment Options
January 28, 2018
Dr Brenton Fargnoli Explains How Quality Measurement Benchmarks Drive Action
February 09, 2018
Jason Harris Discusses the Importance of Real-World Evidence
February 11, 2018
Kathleen Lokay: Implementing Value in Clinical Pathways
February 13, 2018
Dr Brenton Fargnoli on Fixing Issues Physicians Have With EHRs
February 18, 2018
Jason Harris: Improving Patient Understanding and Promoting High-Value Care
March 02, 2018
Dr Thomas Graf on the Impact of New Therapies in Oncology
March 12, 2018
Ian Manners Explains the Impact of Patient Financial Assistance Programs
March 17, 2018
Jason Harris Highlights National Health Council's Recommendations on Real-World Evidence
March 18, 2018
Dr Thomas Graf: How the Impact of Novel Therapies Varies Among Stakeholders
March 22, 2018
Dr Stacey McCullough on the Pharmacist's Role in Patient Education
March 29, 2018
Kathleen Lokay: Incorporating the Latest Research and Supporting Physicians
April 05, 2018
Currently Reading
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
April 06, 2018
Dr Stacey McCullough Discusses Teamwork and Collaboration in Oncology
April 13, 2018

Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage

Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.


Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of new therapies on private insurance coverage for cancer patients.

Transcript

Will novel therapies have an effect on private coverage?

It’s going to drive cost in a way that’s not been seen. I mean, we’ve seen some explosion in pharmacy costs now exceeding often the physician costs for health insurers. That’s gonna leap another factor here, is that the drug costs continue to escalate as new therapies continue to be produced for more and more patients. The potential number of patients that are eligible for some of the drugs that are available is quite small. The newer drugs will have much wider approachable patient panels. So, the ability to impact total cost for insurers, for employers, for the federal government is dramatic. So, I think some employers will thereby not be able to offer coverage because it will become so expensive to their employees which will drive them to different markets. Clearly, there’s a reduction in the insurance mandate. So, I suspect a lot of patients will go from having private coverage to not having private coverage and then we’re going to have a real issue because access to those drugs will be very restricted in that group.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up